Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safety
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
NAFLDsym v2B Beta represents the first release in the faster, sleeker Julia infrastructure
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
DSX is faster, more user-friendly, and scalable for high-performance computing
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
Initiates first steps in updated capital allocation strategy
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
Total revenue of $12 million; Diluted Earnings Per Share (EPS) of $0.06; Both in line with fiscal 2023 guidance and Q1 expectations for revenue seasonality shift.
Provides capital allocation strategy update focusing on corporate development activities, $50 million share repurchase program, and internal investment
Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference Call
Conference call to be on Wednesday, January 4, 2023, at 5 p.m. EST
Simulations Plus and the University of Bath Awarded New FDA Grant
Project will focus on the development of a modeling & simulation framework to support an assessment of bioequivalence for locally-acting drugs in the gastrointestinal tract
Gustavo Mendes Lima Santos Joins the Simulations Plus Regulatory Fellowship
Ex-Anvisa General Manager will contribute to global regulatory strategies involving pharmacometrics
Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code
International organization’s mission is to close the gender gap in technology
Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products
Collaboration combines novel in vitro experimental methods and mechanistic modeling to accelerate development of orally inhaled drug products (OIDPs) and propose alternative approaches for bioequivalence
Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results
Fiscal 2022 revenue increased 16% year-over-year to $53.9 million
Diluted earnings per share increased 28% year-over-year to $0.60
Provides Fiscal 2023 guidance for total revenue of $59.3 million to $62.0 million (+10% to 15%)
Simulations Plus Announces Cash Dividend
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Releases GastroPlus® Version 9.8.3
New update expands the library of virtual populations and enhances connections between software platforms
Simulations Plus to Present at Sidoti Fall Small Cap Investor Conference
Chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking place virtually on September 21-22, 2022.
Simulations Plus to Present at Baird 2022 Global Healthcare Conference
Management will be presenting at Baird’s 2022 Global Healthcare Conference
Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease
ILDsym will enable new software and services revenue by aiding development of therapies for the treatment of patients with ILD as a complication of systemic sclerosis
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)
Extensive data sharing with large pharmaceutical partner will expand property prediction space and improve model performance
Simulations Plus Presented New Scientific Developments at PAGE 2022
Several posters and oral presentations involved the use of MonolixSuite®
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer
Tenured employees support St. Jude in finding cures and saving children
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
Total revenue growth of 17%; Software revenue growth of 16%; Services revenue growth of 19%;
Diluted Earnings Per Share (EPS) growth of 11%;
Board of Directors announces quarterly dividend of $0.06 per share